⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 17, 2026ESMO OpenOpen Access

159eP Prognostic value of the immune checkpoint inhibitor score (IChIS) in palliative immunotherapy-treated non-small cell lung cancer: A real-world study

E.E. Kavak İsmail Dilli Mehmetcan Atak S. Celik O. Aydin Isak Esra Zeynelgil Doğan YAZILITAŞ

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess the prognostic value of the immune checkpoint inhibitor score in patients treated with palliative immunotherapy for non-small cell lung cancer.
Real-world data analysis
Assessment of baseline Hb levels
Comparison of survival outcomes
Higher baseline Hb levels are associated with improved survival
Host-related factors significantly influence immunotherapy outcomes

Implication

Real-world study reveals the prognostic importance of host factors on survival in lung cancer immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kavak et al. (2026) studied this question.

synapsesocial.com/papers/69be34d16e48c4981c672f90 https://doi.org/10.1016/j.esmoop.2026.106466

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer2024 · 2 citations
2Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitorsPrognostic Study · 2025 · 16 citations
3Composite clinical scores in real-world extensive-stage small-cell lung cancer patients treated with chemo-immunotherapyObservational Study · 2026
4Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patientsCohort Study · 2026
5Peripheral blood IFN-γ–producing T-cell subsets and soluble IL-2 receptor as independent prognostic biomarkers in NSCLC treated with immune checkpoint inhibitor–based therapyOriginal Research · 2026